More than 800,000 Americans suffer a heart attack every year. The great majority are preventable. A coronary artery calcium (CAC) scan — a 10-minute, low-radiation procedure costing roughly $100 — can detect calcified plaque in coronary arteries years before it causes a cardiac event. Medicare will cheerfully reimburse $50,000 for the emergency that follows, but not the hundred dollars that could have averted it. In March 2026, the American College of Cardiology and American Heart Association finally gave CAC scanning a central role in national prevention guidelines, recommending it for adults with borderline or intermediate cardiovascular risk where the decision to start statin therapy is uncertain. This came more than three decades after the evidence began accumulating. The delay is not a mystery of science — it is a case study in how payment infrastructure, committee inertia, and clinical habit conspire against cheap, effective prevention. Traditional risk calculators estimate heart attack probability using population-average inputs: age, sex, cholesterol, blood pressure, smoking, diabetes. They estimate likelihood, not the actual presence of disease. A CAC scan measures what is already there. A patient with borderline cholesterol may harbor extensive plaque; another with high cholesterol may have none. A score of zero can reclassify a patient downward, avoiding unnecessary statin prescriptions. A score above 100 flags patients who need aggressive intervention. The scan doesn't replace clinical judgment — it gives clinicians something concrete to judge. The article's illustrative case is telling. A 52-year-old man with borderline cholesterol, regular exercise, good diet, and a family history of heart disease scored low on the standard risk calculator. His CAC score was 220 — substantial plaque for his age. Genetics account for roughly half of cardiovascular risk, but the risk calculators don't incorporate genetics. Without the scan, this patient would have deferred treatment and remained a candidate for a preventable heart attack. Artificial intelligence is now accelerating the economics further. Millions of Americans undergo chest CT scans for unrelated reasons each year, and the cardiovascular information visible on those images is routinely ignored. AI tools can identify coronary and vascular calcification opportunistically from existing scans, standardize reporting, and flag patients for formal preventive evaluation. AI-CAC analysis is also being used to detect soft plaque — a precursor to the calcified plaque seen on traditional scans. This could shift prevention from individual clinical decisions to population-level screening without requiring new imaging appointments. The structural problem is clear: clinical decision-support tools, reimbursement codes, and guideline committees were all built around modifying population-average risk factors, not incorporating individualized imaging. Cardiologists and primary care doctors are constrained by what insurers cover, leaving CAC scanning available mainly to patients who can pay cash. The system is optimized for intervention after catastrophe, not prevention before it. The authors — Arthur Agatston (inventor of the Agatston calcium scoring method) and Oren Mechanic — frame this as a broader pattern: a low-cost, low-risk, well-studied tool sitting at the margins of clinical practice for decades because the systems around it were not built to absorb it. The guidelines have caught up. The reimbursement system has not.
